查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867139

诊断设备市场按产品类型、技术、应用、最终用户和销售管道划分 - 全球预测 2025-2032

Diagnostic Equipment Market by Product Type, Technology, Application, End User, Sales Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，诊断设备市场规模将达到 831.9 亿美元，复合年增长率为 6.76%。

关键市场统计数据
基准年 2024 492.7亿美元
预计年份：2025年 526.5亿美元
预测年份 2032 831.9亿美元
复合年增长率 (%) 6.76%

就当前诊断格局、技术驱动因素以及影响相关人员决策的策略压力，提供了清晰、实用的指导。

诊断设备市场正进入技术快速成熟和营运模式重组阶段，这将直接影响临床路径、实验室工作流程和商业竞争。检测化学、自动化和资料整合方面的进步正在重塑检测方式、结果解读方式以及诊断结果的交付方式。同时，不断变化的管理体制和供应链压力迫使製造商、经销商和终端用户重新思考韧性、合规性和互通性，而这些因素将影响采购週期和产品蓝图。

在此背景下，相关人员必须平衡短期营运重点与长期策略投资。临床实验室优先考虑检测通量、准确性和连接性，而照护现场提供者则寻求能够与远端医疗的紧凑型、坚固耐用的设备。研究机构和医院持续投资于分子诊断和质谱平台，以支持精准医疗倡议，而微生物检测和免疫检测系统对于感染疾病控制和慢性病监测仍然至关重要。

本导言概述了对决策者至关重要的技术和商业性趋势，为后续分析奠定了基础。它强调了技术选择、监管合规和分销策略之间的相互关联，并为后续的详细市场区隔分析、区域分析和竞争考察设定了预期目标。贯穿始终，本导言都专注于提供可操作的洞见：将技术进步和政策变化转化为对产品开发、采购和伙伴关係决策的明确启示。

技术创新、医疗服务体系重组和监管加强的整合将如何重塑诊断设备的发展重点和竞争格局？

诊断产业正经历一场变革浪潮，其驱动力包括技术融合、医疗服务模式的转变以及对数据驱动型诊断日益增长的需求。先进分子技术与自动化和数位分析的融合，使得检测速度更快、灵敏度更高，从而支持早期疗育和精准治疗方案的选择。同时，小型化和稳健化设计正在加速复杂检测从中心实验室向更贴近患者的场所转移，改变传统的检测经济模式，并催生出新的分销管道关係。

医疗服务模式的转型也正在推动产品需求的重新定义。随着医疗系统优先考虑以价值为导向的医疗和人群健康管理，它们会选择那些能够展现临床效用、成本效益以及对患者预后产生可衡量影响的诊断解决方案。这种转变要求仪器不仅要具备卓越的分析性能，还要能够无缝整合到临床工作流程和报告系统中。此外，远端医疗和家庭监测的兴起也推动了对易于使用、互联互通的诊断工具的需求，这些工具能够在扩大服务范围的同时，维持诊断品质。

监管预期和支付方审查力度的同步提升，进一步提高了证据产生和上市后监测的标准。製造商现在必须制定涵盖真实世界效能数据、互通性测试和网路安全保障的全生命週期证据策略。总而言之，这些变革要求製造商和医疗系统从系统观点出发：投资于平台的多功能性，在整个诊断生态系统中建立伙伴关係关係，并采用稳健的数据策略以保持竞争优势。

检验美国近期关税变化如何推动诊断产业供应链多元化、筹资策略调整和产品重新设计。

美国近期关税调整及更广泛的贸易政策环境已对诊断设备零件和成品供应链造成了显着影响。关税相关的成本压力正在影响高精度仪器所需专用耗材、光学元件和电子元件的采购决策。因此，製造商和经销商被迫重新评估其供应商网路、库存管理政策和定价策略，以维持利润率并按时交付。

关税的累积影响正在加速供应链多元化，并促使企业寻求近岸外包，以降低关税波动和运输延误带来的风险。采购部门在比较不同供应商时，越来越多地进行总体拥有成本分析，将关税、物流成本、前置作业时间和合规性等因素纳入考量。在某些情况下，企业会建立策略伙伴关係和长期供应商协议，以稳定成本并确保关键原料的优先采购。

除了采购之外，关税也在推动可行范围内的重新设计和组件替换方面的创新，鼓励工程团队评估模组化设计，以便在不影响分析性能的前提下使用替代组件。检验这些替代方案的监管流程需要周密的计划，因为变更可能需要额外的检验和核准步骤。对于临床实验室和医疗系统而言，直接影响将是更加关注合约条款、制定紧急时应对计画以及严格监控供应商绩效，以防止营运中断并维持病患服务的连续性。

基于全面细分的洞察，揭示影响竞争机会的不同产品、技术、应用、最终用户和通路动态。

要了解市场动态，需要详细阐述多个细分维度，每个维度对产品开发和商业策略都有不同的影响。按产品类型划分，市场涵盖血液气体和电解质分析仪、临床化学分析仪、血液学和血液凝固检验系统、免疫检测平台、微生物实验室及设备（包括细菌学、真菌学、寄生虫学和病毒学工作流程）、分子诊断工具（例如数位PCR、等温扩增和即时PCR技术）以及尿液分析仪。每个产品组都有其自身的生命週期、监管要求和客户购买模式，这往往需要更高程度的实验室整合和专门的耗材策略，尤其是在分子诊断和微生物学领域。

基于技术的细分进一步区分了竞争格局。这包括层析法解决方案（包括气相层析法和高效液相层析）、流式细胞技术系统、免疫检测分析技术、质谱平台（分为液相层析法质谱仪和基质辅助雷射脱附游离）以及聚合酵素链锁反应）仪器。技术选择决定了资本投入、验证复杂性和服务需求。质谱和层析法常用于科研和参考实验室，而免疫检测和基于PCR的系统在临床诊断和照护现场（POC​​）应用中发挥核心作用。

应用细分突显了临床需求集中的领域。心臟病学、糖尿病监测、基因检测、感染疾病诊断、肿瘤学和产前检测各自具有独特的性能和监管要求。肿瘤学和基因检测的诊断方法通常强调高分析灵敏度和针对临床终点的广泛验证，而糖尿病监测和传染病检查优先考虑快速出结果和易于操作，以便广泛应用于临床。

终端使用者细分有助于明确学术研究机构、诊所、诊断实验室、医院和照护现场场所的采用模式。照护现场可进一步细分为糖尿病监测、传染病检查和妊娠检测等情境。终端用户的购买週期、服务期望和整合需求各不相同，了解这些差异对于设计销售活动和支援模式至关重要。最后，销售管道细分将直销、分销商和线上销售确定为主要的市场进入途径，每种途径都有不同的利润结构、覆盖范围权衡和客户关係模式。将这些细分观点迭加起来，可以全面了解市场机会和竞争态势，有助于优化产品定位和通路策略。

区域趋势和细緻的市场进入考量正在影响美洲、欧洲、中东和非洲以及亚太地区的诊断技术应用。

区域趋势是诊断生态系中产品需求、监管路径和商业模式的根本决定因素。在美洲，需求受集中式医疗服务体系、强大的私人实验室以及强调临床效用证据的报销模式的影响。该地区的监管流程和与支付方的互动需要可靠的临床和经济数据，因此製造商通常优先考虑与大型实验室网路和医院系统合作，以确保规模化和市场认可。

欧洲、中东和非洲地区（EMEA）环境高度多元化，各国不同的报销政策、监管协调工作以及公共卫生优先事项都会影响实施时间表。监管协调工作增加了区域商业规模化发展的机会，但製造商也必须应对不同的采购惯例和价格压力。此外，一些国家的公共卫生计画和中心实验室网路推动了对高通量系统的需求，而其他市场则优先考虑分散式或照护现场解决方案。

亚太地区是一个涵盖已开发经济体和新兴经济体的广大市场，部分都市区则面临高需求且对成本高度敏感的市场。该地区的製造能力和庞大的患者群体使其既是重要的战略生产基地，也是重要的终端市场。市场进入和扩大策略必须应对不同的法规结构、本地伙伴关係模式和价格敏感性，同时也要抓住数位诊断和人群健康管理创新试点倡议的机会。

设备製造商、利基创新者和服务供应商之间的关键竞争趋势和策略行动正在推动市场整合和差异化。

诊断设备市场的竞争格局由成熟的跨国製造商、专业技术供应商和新兴创新者组成。大型设备製造商持续投资于整合自动化、互联互通和扩展检测专案的平台，以锁定实验室客户并持续创造耗材需求。同时，专注于高灵敏度质谱、数位PCR和标靶分子工作流程等细分技术的专业公司也在不断提升自身能力，以应对特定的临床挑战，并吸引科研和参考实验室客户。

透过共同开发契约、数据共用伙伴关係和联合检验项目，设备供应商与临床合作伙伴之间的协作模式日益普遍，加速了设备的应用和证据的累积。在高度复杂的环境中，运作和快速解决问题至关重要，因此卓越的服务和支援仍然是关键的竞争优势。能够展现强大临床价值、更低整体拥有成本或简化工作流程的新兴参与企业有机会取代传统方法，尤其是在分散式和照护现场环境中，便利性和连结性至关重要。

策略性併购活动和伙伴关係策略正在重塑竞争格局，现有企业透过收购来增强自身能力，并拓展其在分子诊断、资讯科学和耗材领域的业务。决策者必须密切注意产品蓝图、合作网络和实证医学计画的演变，因为这些因素将决定企业的长期竞争地位以及满足日益融合的临床需求的能力。

为领导者提供切实可行的策略性倡议，以增强产品适应性、供应链韧性、证据产生能力以及伙伴关係主导的市场扩张。

行业领导者应采取一系列务实且具有前瞻性的倡议，以维持市场地位并抓住新的机会。首先，应优先考虑平台的多功能性和模组化设计，使产品能够快速适应不断变化的测试要求和组件供应情况。这有助于降低供应衝击带来的风险，并延长产品生命週期。其次，应投资于整合临床结果、卫生经济学和真实世界数据（RWD）的实证策略，以支持在不同医疗环境中进行医疗保险报销谈判和临床应用。

增强供应链韧性也是一项优先事项。这包括供应商多元化、确保关键零件的长期合同，以及探索区域製造方案以降低关税和物流风险。在商业方面，必须优化通路策略，以平衡与高价值客户的直接交易与透过合作伙伴和数位化平台进行高效分销以扩大覆盖范围之间的关係。加强服务交付和远距离诊断能力将提高系统运转率和客户满意度，从而创造竞争优势。

最后，我们将与医疗系统、研究机构和数位医疗服务提供者建立策略性合作伙伴关係，共同开发整合解决方案，以应对工作流程和互通性的挑战。这些合作将加速产品检验，拓展临床应用场景，并为将诊断技术融入以价值为导向的医疗模式铺路。落实这些建议需要跨部门协作、明确的投资重点以及可衡量的里程碑，以便根据市场变化追踪进度并及时调整方向。

我们采用稳健的多源研究途径，结合专家访谈、技术检验和文件分析，提供可操作的诊断市场情报。

本摘要的研究旨在透过结合一级资讯来源和二级资讯来源、专家访谈以及技术检验审查等方法，确保提供平衡客观的视角。一级资讯来源包括对医院、参考实验室和照护现场机构的采购人员、实验室主任和研发经理进行的结构化访谈，并辅以与设备和耗材製造商的产品和法规专家的交流。这些定性研究深入洞察了各类终端用户的采用驱动因素、服务期望和采购趋势。

二级研究涵盖了同行评审文献、监管指南和技术白皮书，以检验技术性能特征和证据要件。市场情报收集优先考虑公开文件、产品文件和会议报告，追踪产品蓝图、近期核准情况和合作活动。技术检验审查评估了分析能力、工作流程整合和资料互通性，以涵盖实际实施方面的考虑因素。

我们的分析方法结合了质性访谈的主题综合分析和技术比较评估，旨在揭示对产品设计、商业化和监管策略的影响。我们避免依赖任何单一资讯来源，并与多方相关人员最后覆核，以确保分析结果的稳健性和相关性，从而为寻求可操作指导而非量化市场预测的决策者提供切实可行的建议。

将策略重点和实际考量相结合，以将诊断创新转化为切实可行的应用和临床影响。

摘要，技术融合、医疗服务模式的转变以及监管和商业审查的加强正在重塑诊断行业。那些能够将产品策略与临床工作流程相契合、投资于实证医学并建立稳健供应链的相关人员，将更有能力应对不确定性并创造价值。集中式实验室能力与分散式检查模式之间的相互作用将继续为各种检测方式创造差异化机会，而分子诊断和先进质谱技术将在精准医疗应用中保持其战略重要性。

决策者应将当前环境视为一个重视敏捷性、伙伴关係以及以数据驱动的临床和经济价值论证的环境。卓越的服务营运、对组件变更的监管准备以及周全的通路策略，都是技术创新的必要补充。透过专注于平台灵活性、互通性以及对能够引起支付方和临床医生共鸣的证据进行投资，各机构可以改善其技术采纳路径并保持竞争优势。

最终，基于严格检验和协作商业化的积极调整将使製造商和供应商能够将诊断创新转化为患者照护和系统效率的实际改进。本摘要旨在提供策略观点，指导后续步骤，帮助各组织优先考虑工作重点并合理分配资源，以达到最大效益。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合人工智慧驱动的影像分析工具，以提高诊断准确性和效率
  • 对快速照护现场分子诊断的需求日益增长，以支援分散式医疗服务。
  • 云端基础的资料管理平台正变得越来越一体化，从而创建了一个在医疗机构之间即时共用诊断结果的系统。
  • 开发用于在单次检测中同时检测多种疾病生物标记的多重免疫检测试剂盒
  • 携带式超音波设备取得了进步，影像清晰度更高，测量功能也更加自动化。
  • 利用全切片成像和人工智慧演算法，透过扩展数位病理解决方案来加速癌症诊断。
  • 基因和表观遗传生物标记识别技术推动了个人化诊断检测的发展
  • 非侵入性液态生物检体技术的出现，使得早期检测和监测血液样本中的癌症突变成为可能。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按产品类型分類的诊断设备市场

  • 血气和电解质
  • 临床化学
  • 血液学和血液凝固检验
  • 免疫检测
  • 微生物学
    • 细菌学
    • 真菌学
    • 寄生虫学
    • 病毒学
  • 分子诊断
    • 数位PCR
    • 等温扩增
    • 即时PCR
  • 尿液检查

第九章 按技术分類的诊断设备市场

  • 层析法
    • 气相层析法
    • 高效液相层析
  • 流式细胞技术
  • 免疫检测技术
  • 质谱分析
    • 液相层析法质谱法
    • 基质辅助雷射解吸/电离
  • 聚合酵素链锁反应

第十章 按应用分類的诊断设备市场

  • 心臟病学
  • 糖尿病监测
  • 基因检测
  • 感染疾病
  • 肿瘤学
  • 产前检查

第十一章 按最终用户分類的诊断设备市场

  • 学术研究机构
  • 诊所
  • 诊断实验室
  • 医院
  • 护理点
    • 糖尿病监测
    • 传染病检查
    • 妊娠测试

第十二章 按销售管道分類的诊断设备市场

  • 直销
  • 经销商
  • 线上销售

第十三章 各地区的诊断设备市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 诊断设备市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国诊断设备市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Danaher Corporation
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Sysmex Corporation
    • Ortho Clinical Diagnostics, Inc.
    • QIAGEN NV
Product Code: MRR-5D693B46C826

The Diagnostic Equipment Market is projected to grow by USD 83.19 billion at a CAGR of 6.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 49.27 billion
Estimated Year [2025] USD 52.65 billion
Forecast Year [2032] USD 83.19 billion
CAGR (%) 6.76%

A clear, actionable orientation to the current diagnostic equipment landscape, technological drivers, and strategic pressures shaping stakeholder decisions

The diagnostic equipment landscape has entered a period of rapid technical maturation and operational recalibration that directly affects clinical pathways, laboratory workflows, and commercial competition. Advances in assay chemistry, automation, and data integration are reshaping how tests are performed, how results are interpreted, and where diagnostics are delivered. Simultaneously, evolving regulatory regimes and supply chain pressures are forcing manufacturers, distributors, and end users to rethink resilience, compliance, and interoperability in ways that will influence procurement cycles and product roadmaps.

Against this backdrop, stakeholders must balance near-term operational priorities with long-term strategic investments. Clinical laboratories are prioritizing throughput, accuracy, and connectivity, while point-of-care providers demand compact, robust devices that integrate seamlessly with electronic health records and telehealth platforms. Research organizations and hospitals continue to invest in molecular and mass spectrometry platforms to support precision medicine initiatives, while microbiology and immunoassay systems remain essential for infectious disease management and chronic disease monitoring.

This introduction frames the subsequent analysis by outlining the technical and commercial vectors that are most consequential for decision-makers. It underscores the interconnected nature of technology choices, regulatory compliance, and distribution strategies, and sets expectations for the detailed segmentation, regional, and competitive insights that follow. Throughout, the emphasis is on actionable intelligence: translating technical evolution and policy shifts into clear implications for product development, purchasing, and partnership decisions.

How converging technological advances, care delivery reorganization, and regulatory rigor are reshaping diagnostic equipment priorities and competitive dynamics

The diagnostic equipment sector is experiencing transformative shifts driven by converging technologies, shifting care delivery models, and intensifying demands for data-driven diagnostics. The integration of advanced molecular techniques with automation and digital analytics is enabling faster, more sensitive assays that support earlier intervention and more precise treatment selection. Concurrently, miniaturization and ruggedized designs are accelerating the migration of complex testing from centralized laboratories to near-patient environments, altering traditional laboratory economics and prompting new channel relationships.

Care delivery transformation is also redefining product requirements. As health systems prioritize value-based care and population health, diagnostic solutions that demonstrate clinical utility, cost-effectiveness, and measurable impact on patient outcomes gain preference. This shift promotes devices that deliver not only analytical performance but also seamless integration into clinical workflows and reporting systems. Moreover, the rise of telemedicine and home-based monitoring is increasing demand for easy-to-use, connected diagnostic tools that maintain quality while expanding access.

Regulatory expectations and payer scrutiny are simultaneously rising, creating a higher bar for evidence generation and post-market surveillance. Manufacturers now need to plan for lifecycle evidence strategies that encompass real-world performance data, interoperability testing, and cybersecurity assurance. Taken together, these transformations require manufacturers and health systems to adopt a systems-level perspective: investing in platform versatility, partnerships across the diagnostic ecosystem, and robust data strategies to sustain competitive advantage.

Examining how recent United States tariff shifts have prompted supply chain diversification, procurement recalibration, and product redesign imperatives across diagnostics

Recent tariff adjustments and the broader trade policy environment in the United States have created measurable disruption across supply chains for diagnostic equipment components and finished goods. Tariff-related cost pressures have influenced sourcing decisions for specialized consumables, optics, and electronic components that underpin high-precision instruments. As a result, manufacturers and distributors have had to re-evaluate supplier networks, inventory policies, and pricing strategies to maintain margin profiles and delivery commitments.

The cumulative effect of tariffs has been to accelerate diversification of supply bases and to promote near-shoring as organizations seek to mitigate exposure to tariff volatility and shipping delays. Procurement teams are increasingly conducting total-cost-of-ownership analyses that account for duties, logistics costs, lead times, and regulatory conformity when comparing alternative suppliers. In some instances, strategic partnerships and long-term supplier agreements have emerged as a means to stabilize costs and secure priority access to critical input materials.

Beyond procurement, tariffs have encouraged innovation in redesign and component substitution where feasible, prompting engineering teams to evaluate modular designs that can accept alternative components without compromising analytical performance. Regulatory pathways for validating such substitutions require careful planning, as changes may trigger new verification or approval steps. For clinical laboratories and health systems, the immediate implication is heightened attention to contract terms, contingency planning, and supplier performance monitoring to prevent operational disruptions and maintain continuity of patient services.

Comprehensive segmentation-driven insights that reveal distinct product, technology, application, end-user, and channel dynamics shaping competitive opportunity

Understanding market dynamics requires a nuanced view across multiple dimensions of segmentation, each of which presents distinct implications for product development and commercial strategy. Based on product type, the landscape spans Blood Gas And Electrolyte instruments, Clinical Chemistry analyzers, Hematology And Coagulation systems, Immunoassay platforms, Microbiology laboratories and instruments that include bacteriology, mycology, parasitology, and virology workflows, Molecular Diagnostics tools such as digital PCR, isothermal amplification, and real-time PCR technologies, and Urinalysis devices. Each product family follows its own lifecycle, regulatory expectations, and customer buying patterns, with molecular and microbiology modalities often demanding higher laboratory integration and specialized consumable strategies.

Technology-based segmentation further differentiates competitive dynamics, encompassing chromatographic solutions including gas chromatography and high performance liquid chromatography, flow cytometry systems, immunoassay technologies, mass spectrometry platforms differentiated into liquid chromatography mass spectrometry and matrix assisted laser desorption ionization, and polymerase chain reaction instruments. Technology choices drive capital intensity, validation complexity, and service needs; mass spectrometry and chromatography are frequently leveraged in research and reference laboratories, while immunoassays and PCR-based systems play central roles in clinical diagnostics and point-of-care applications.

Application segmentation highlights where clinical demand is concentrated, with cardiology, diabetes monitoring, genetic testing, infectious disease diagnostics, oncology, and prenatal testing each creating unique performance and regulatory requirements. Diagnostics intended for oncology and genetic testing typically emphasize high analytical sensitivity and extensive validation against clinical endpoints, whereas diabetes monitoring and infectious disease testing prioritize rapid turnaround and operational simplicity for widespread clinical use.

End-user segmentation clarifies adoption patterns across academic research institutes, clinics, diagnostic laboratories, hospitals, and point-of-care settings, with point-of-care further subdivided into diabetes monitoring, infectious disease testing, and pregnancy testing scenarios. End users differ in purchasing cycles, service expectations, and integration needs, and understanding these distinctions is critical when designing sales motions and support models. Lastly, sales channel segmentation identifies direct sales, distributors, and online sales as primary routes to market, each with distinct margin structures, coverage trade-offs, and customer relationship models. Layering these segmentation lenses enables a composite view of opportunity and competitiveness that supports tailored product positioning and channel strategies.

Regional dynamics and nuanced market access considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape diagnostics adoption

Regional dynamics are a fundamental determinant of product demand, regulatory pathways, and commercial models across the diagnostics ecosystem. In the Americas, demand is shaped by concentrated healthcare delivery systems, a strong private laboratory sector, and reimbursement models that emphasize evidence of clinical utility. Regulatory processes and payer interactions in this region require robust clinical and economic data, and manufacturers often prioritize integration with large laboratory networks and hospital systems to secure scale and visibility.

Europe, the Middle East & Africa presents a highly heterogeneous environment where differing national reimbursement approaches, regulatory harmonization efforts, and public health priorities influence adoption timetables. Regulatory alignment initiatives increase opportunities for regional commercial scale, but manufacturers must navigate variable procurement practices and pricing pressures. In addition, public health programs and centralized laboratory networks in some countries drive demand for high-throughput systems, while other markets prioritize decentralized or point-of-care solutions.

Asia-Pacific includes a broad mix of advanced and emerging markets characterized by rapid adoption of novel technologies in some urban centers, alongside high-volume, cost-sensitive demand in other jurisdictions. The region's manufacturing capabilities and large patient populations make it both a strategic production base and a significant end-market. Market entry and expansion strategies here must address diverse regulatory frameworks, local partnership models, and price sensitivity, while also leveraging opportunities to pilot innovations in digital diagnostics and population health initiatives.

Key competitive trends and strategic behaviors among instrument manufacturers, niche innovators, and service providers driving market consolidation and differentiation

Competitive dynamics in the diagnostic equipment landscape reflect a mix of established multinational manufacturers, specialized technology providers, and emerging innovators. Leading instrument makers continue to invest in integrated platforms that combine automation, connectivity, and expanded assay menus to lock in laboratory customers and create recurring consumable demand. At the same time, specialized firms focused on niche technologies-such as high-sensitivity mass spectrometry, digital PCR, or targeted molecular workflows-are advancing capabilities that address specific clinical gaps and attract research and reference laboratory customers.

Collaborative models between instrument vendors and clinical partners are becoming more common, with co-development agreements, data-sharing partnerships, and joint validation programs used to accelerate adoption and build evidence. Service and support excellence remain a differentiator, particularly in high-complexity settings where uptime and rapid issue resolution are critical. New entrants that can demonstrate compelling clinical value, lower total cost of ownership, or simplified workflows have opportunities to displace legacy approaches, particularly in decentralized and point-of-care environments where convenience and connectivity matter most.

Strategic M&A activity and partnership strategies are reshaping competitive portfolios, as established players acquire capabilities in molecular diagnostics, informatics, or consumables to broaden their offerings. For decision-makers, the imperative is to monitor how product roadmaps, alliance networks, and evidence generation programs evolve, since these elements will determine long-term competitiveness and the ability to meet increasingly integrated clinical requirements.

Practical strategic moves for leaders to strengthen product adaptability, supply resilience, evidence generation, and partnership-driven market expansion

Industry leaders should adopt a pragmatic and forward-looking set of actions to preserve market position and capture emerging opportunities. First, prioritize platform versatility and modularity so products can be quickly adapted to changing assay requirements and component availability; this reduces vulnerability to supply shocks and extends product lifecycle relevance. Next, invest in evidence strategies that integrate clinical outcomes, health economics, and real-world performance data to support reimbursement discussions and clinical adoption in diverse care settings.

Strengthening supply chain resilience is another priority. This includes diversifying supplier bases, securing long-term agreements for critical components, and considering regional manufacturing options to mitigate tariff and logistics exposure. Commercially, refine channel strategies to balance direct engagement with high-value customers and efficient distribution through partners or digital platforms for broader reach. Enhancing service delivery and remote diagnostics capability will improve system uptime and customer satisfaction, creating a competitive edge.

Finally, pursue strategic partnerships with healthcare systems, research institutions, and digital health providers to co-develop integrated solutions that address workflow and interoperability challenges. Such collaborations can accelerate product validation, expand clinical use cases, and create pathways to embed diagnostics within value-based care models. Executing these recommendations will require cross-functional alignment, clear investment priorities, and measurable milestones to track progress and adjust course as market conditions evolve.

A robust, multi-source research approach combining expert interviews, technical validation, and document analysis to produce actionable diagnostic market intelligence

The research underpinning this summary is based on a triangulation of primary and secondary sources, expert interviews, and technology validation reviews designed to ensure balanced, objective insight. Primary inputs included structured interviews with procurement leaders, laboratory directors, and R&D managers across hospital, reference laboratory, and point-of-care settings, supplemented by conversations with product and regulatory specialists within instrument and consumable firms. These qualitative engagements provided depth on adoption drivers, service expectations, and procurement dynamics across diverse end users.

Secondary research encompassed peer-reviewed literature, regulatory guidance, and technical white papers to validate technology performance characteristics and evidence requirements. Market intelligence collection prioritized public filings, product documentation, and conference proceedings to track product roadmaps, recent approvals, and partnership activity. Technology validation reviews assessed analytical capabilities, workflow integration, and data interoperability to understand practical deployment considerations.

Analytical methods integrated thematic synthesis of qualitative interviews with comparative technology assessments to surface implications for product design, commercialization, and regulatory strategy. Care was taken to avoid reliance on any single information source, and findings were cross-checked with multiple stakeholders to ensure robustness and relevance for decision-makers seeking actionable guidance rather than numeric market projections.

Synthesis of strategic priorities and practical considerations for translating diagnostic innovation into resilient adoption and clinical impact

In summary, the diagnostic equipment sector is being reshaped by technological convergence, shifting care delivery models, and heightened regulatory and commercial scrutiny. Stakeholders who align product strategies with clinical workflows, invest in evidence generation, and build resilient supply chains will be better positioned to navigate uncertainty and capture value. The interplay between centralized laboratory capabilities and decentralized testing models will continue to create differentiated opportunities across modalities, with molecular diagnostics and advanced mass spectrometry retaining strategic importance for precision applications.

Decision-makers should view the current environment as one that rewards agility, partnership, and data-driven demonstration of clinical and economic value. Operational excellence in service, regulatory readiness for component changes, and thoughtful channel strategies are essential complements to technological innovation. By focusing investments on platform flexibility, interoperability, and evidence that resonates with payers and clinicians, organizations can improve adoption trajectories and sustain competitive differentiation.

Ultimately, proactive adaptation-grounded in rigorous validation and collaborative commercialization-will enable manufacturers and providers to translate diagnostic innovations into meaningful improvements in patient care and system efficiency. The insights in this summary are intended to inform those next steps, offering a strategic lens through which organizations can prioritize initiatives and allocate resources for maximum impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven image analysis tools to enhance diagnostic accuracy and throughput
  • 5.2. Rising demand for rapid point-of-care molecular diagnostics to support decentralized healthcare delivery
  • 5.3. Growing integration of cloud-based data management platforms for real-time diagnostic result sharing across clinics
  • 5.4. Development of multiplex immunoassay panels for simultaneous detection of multiple disease biomarkers in a single assay
  • 5.5. Advancements in portable ultrasound devices with enhanced imaging clarity and automated measurement capabilities
  • 5.6. Expansion of digital pathology solutions leveraging whole slide imaging and AI algorithms for faster cancer diagnosis
  • 5.7. Shift toward personalized diagnostic testing driven by genetic and epigenetic biomarker identification technologies
  • 5.8. Emergence of non-invasive liquid biopsy techniques for early detection and monitoring of cancer mutations in blood samples

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diagnostic Equipment Market, by Product Type

  • 8.1. Blood Gas And Electrolyte
  • 8.2. Clinical Chemistry
  • 8.3. Hematology And Coagulation
  • 8.4. Immunoassay
  • 8.5. Microbiology
    • 8.5.1. Bacteriology
    • 8.5.2. Mycology
    • 8.5.3. Parasitology
    • 8.5.4. Virology
  • 8.6. Molecular Diagnostics
    • 8.6.1. Digital Pcr
    • 8.6.2. Isothermal Amplification
    • 8.6.3. Real Time Pcr
  • 8.7. Urinalysis

9. Diagnostic Equipment Market, by Technology

  • 9.1. Chromatography
    • 9.1.1. Gas Chromatography
    • 9.1.2. High Performance Liquid Chromatography
  • 9.2. Flow Cytometry
  • 9.3. Immunoassay Technology
  • 9.4. Mass Spectrometry
    • 9.4.1. Liquid Chromatography Mass Spectrometry
    • 9.4.2. Matrix Assisted Laser Desorption Ionization
  • 9.5. Polymerase Chain Reaction

10. Diagnostic Equipment Market, by Application

  • 10.1. Cardiology
  • 10.2. Diabetes Monitoring
  • 10.3. Genetic Testing
  • 10.4. Infectious Disease
  • 10.5. Oncology
  • 10.6. Prenatal Testing

11. Diagnostic Equipment Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Clinics
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals
  • 11.5. Point Of Care
    • 11.5.1. Diabetes Monitoring
    • 11.5.2. Infectious Disease Testing
    • 11.5.3. Pregnancy Testing

12. Diagnostic Equipment Market, by Sales Channel

  • 12.1. Direct Sales
  • 12.2. Distributors
  • 12.3. Online Sales

13. Diagnostic Equipment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Diagnostic Equipment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Diagnostic Equipment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Danaher Corporation
    • 16.3.4. Siemens Healthineers AG
    • 16.3.5. Thermo Fisher Scientific Inc.
    • 16.3.6. Becton, Dickinson and Company
    • 16.3.7. bioMerieux SA
    • 16.3.8. Sysmex Corporation
    • 16.3.9. Ortho Clinical Diagnostics, Inc.
    • 16.3.10. QIAGEN N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DIAGNOSTIC EQUIPMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DIAGNOSTIC EQUIPMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DIAGNOSTIC EQUIPMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BLOOD GAS AND ELECTROLYTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BLOOD GAS AND ELECTROLYTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BLOOD GAS AND ELECTROLYTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BLOOD GAS AND ELECTROLYTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BLOOD GAS AND ELECTROLYTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BLOOD GAS AND ELECTROLYTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HEMATOLOGY AND COAGULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HEMATOLOGY AND COAGULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HEMATOLOGY AND COAGULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HEMATOLOGY AND COAGULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HEMATOLOGY AND COAGULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HEMATOLOGY AND COAGULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BACTERIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BACTERIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BACTERIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BACTERIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BACTERIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY BACTERIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MYCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MYCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MYCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MYCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MYCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MYCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PARASITOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PARASITOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PARASITOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PARASITOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PARASITOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PARASITOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY VIROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY VIROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY VIROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY VIROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY VIROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY VIROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY URINALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY URINALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY URINALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY URINALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY URINALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY IMMUNOASSAY TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY LIQUID CHROMATOGRAPHY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY LIQUID CHROMATOGRAPHY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY LIQUID CHROMATOGRAPHY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY LIQUID CHROMATOGRAPHY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY LIQUID CHROMATOGRAPHY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY LIQUID CHROMATOGRAPHY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MATRIX ASSISTED LASER DESORPTION IONIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MATRIX ASSISTED LASER DESORPTION IONIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MATRIX ASSISTED LASER DESORPTION IONIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MATRIX ASSISTED LASER DESORPTION IONIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MATRIX ASSISTED LASER DESORPTION IONIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MATRIX ASSISTED LASER DESORPTION IONIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIABETES MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PREGNANCY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PREGNANCY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PREGNANCY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PREGNANCY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PREGNANCY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PREGNANCY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL DIAGNOSTIC EQUIPMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY CHROMATOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY MASS SPECTROMETRY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY POINT OF CARE, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA DIAGNOSTIC EQUIPMENT MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH A